Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Apr-Jun;6(2):427-430.
doi: 10.4103/jfmpc.jfmpc_323_16.

Peripheral T-cell lymphoma, not otherwise specified

Kunal Kishor Jha  1 , Suresh K Gupta  2 , Harpreet Saluja  3 , Nuwadatta Subedi  4
Affiliations
Case Reports

Peripheral T-cell lymphoma, not otherwise specified

Kunal Kishor Jha et al. J Family Med Prim Care. 2017 Apr-Jun.

Abstract

The peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) belongs to a heterogeneous class of aggressive neoplasms. Although several morphologic subtypes of this tumor have been described, no particular genetic, immunological, or distinct clinical features define this disease. Patients can experience night sweats, fever, lymphadenopathy, weight loss, splenomegaly, and/or skin changes. Common laboratory tests reveal that patients have anemia, thrombocytosis, lymphocytosis, eosinophilia, hypergammaglobulinemia, or increased lactate dehydrogenase. In this case study, a patient presented with massive lymphadenopathy and right lower limb swelling, which he developed over 6 weeks. A tissue biopsy and supporting investigations confirmed the diagnosis of PTCL, NOS.

Keywords: CHOP regimen; lymphoma; peripheral T-cell lymphoma not otherwise specified; pralatrexate.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Computed tomography of the abdomen and pelvis showing a right inguinal lymph node mass measuring up to 11.3 cm × 6.3 cm
Figure 2
Figure 2
A 2.4 cm cystic or necrotic component in the inferior lateral position of the mass
Figure 3
Figure 3
A core biopsy showing diffuse effacement of nodular architecture by small to intermediate-sized lymphocytes with moderate cytologic atypia
Figure 4
Figure 4
CD3-positive immune cell infiltrates
See this image and copyright information in PMC

References

    1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032. - PMC - PubMed
    1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–95. - PubMed
    1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909–18. - PubMed
    1. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: Prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25:2211–7. - PMC - PubMed
    1. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–7. - PubMed

Publication types